Abstract

Objectives: Niosomes are non-ionic surfactant based multilamellar or unilamellar vesicles with aqueous solution of solute that is enclosed by a membrane. Etodolac is an indole acetic acid derivative with half-life of 4 to 7hrs. It is used for the treatment of Rheumatoid arthritis. Whenever used orally, it has many systemic side effects, so it is not preferred orally. The aim of present study was to develop niosomes of Etodolac to avoid all drawbacks associated with it like first pass metabolism and side effects. Methods: In present study four niosomes formulations of Etodolac were successfully developed by modified ether injection technique using different nonionic surfactant i.e. Span 20, Span 40, Tween 20, Tween 40 and cholesterol. Formulations were evaluated for different parameters like particle size, entrapment efficiency, in-vitro release, stability studies. Results: Niosomes formulations of batch N3 shows maximum mean particle diameter i.e. 2.46 µm. The entrapment efficiency of the niosomes was between 66.52-78.32%. The entrapment efficiency was found to be higher with the batch N4 (78.32%). The cumulative percent drug release after 10 hrs of the Etodolac niosomes in between 40.59-78.55%. 68.5% for N1, 50.49% for N2, 40.59 for N3 and 78.55 for N4. Accelerated stability studies for 12 weeks revealed that the Etodolac niosomes formulations of batch N4 were stable at up to 450C. Conclusion: Study concludes that Etodolac can be delivered by niosomes dosage form effectively and all limitations associated with it can be avoided. Peer Review History: Article received on-16 September, Revised 24 October, Accepted 30 October, Available online 15 November 2016 UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file: Reviewer's Comments: Average Peer review marks at initial stage: 4.5/10 Average Peer review marks at publication stage: 7.5/10 Reviewer(s) detail: Dr. Barkat Ali Khan, Kampala International University , Uganda, barki.gold@gmail.com Prof. Dr. Kapil Kumar, Global Institute of Pharmaceutical Education and Research, Kashipur, US Nagar, Uttarakhand, India, kapil5november@gmail.com Similar Articles: INVESTIGATION OF PRONIOSOMES GEL AS A PROMISING CARRIER FOR TRANSDERMAL DELIVERY OF GLIMEPIRIDE

Highlights

  • Niosomes containing Etodolac were prepared by modified ether injection technique using nonionic surfactant and cholesterol at different concentrations (Table 1)

  • The role of the drug delivery system is limited to a drug package just meant for convenience and administration but to bring a required change in therapeutic efficacy and safety by carrying the drug molecules to the desired site in the most convenient manner

  • In present study four Etodolac niosomes formulations were successfully developed by using different surfactants i.e. Span 20, Span 40, Tween 20, Tween 40 by modified ether injection method

Read more

Summary

Objectives

Niosomes are non-ionic surfactant based multilamellar or unilamellar vesicles with aqueous solution of solute that is enclosed by a membrane. Etodolac is an indole acetic acid derivative with half-life of 4 to 7hrs. It is used for the treatment of Rheumatoid arthritis. The aim of present study was to develop niosomes of Etodolac to avoid all drawbacks associated with it like first pass metabolism and side effects. Methods: In present study four niosomes formulations of Etodolac were successfully developed by modified ether injection technique using different nonionic surfactant i.e. Span 20, Span 40, Tween 20, Tween 40 and cholesterol. Formulations were evaluated for different parameters like particle size, entrapment efficiency, in-vitro release, stability studies. Accelerated stability studies for 12 weeks revealed that the Etodolac niosomes formulations of batch N4 were stable at up to 450C.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call